NeuroMetrix, Inc. (Nasdaq: NURO) reported today that industry insiders
got their first look at Quell during day 1 of this year’s International
Consumer Electronics Show (CES).
Quell utilizes NeuroMetrix’s proprietary non-invasive neurostimulation
technology to provide relief from chronic pain, particularly nerve pain
such as due to diabetes and lower back problems. The advanced wearable
device is lightweight and can be worn during the day while active, and
at night while sleeping. It has been cleared by the FDA for treatment of
chronic pain without a prescription. Users of the device will also have
the option of using their smartphone to automatically track and
personalize their pain therapy.
The response to Quell has been positive with PCWorld reporting, “Now
there’s finally a consumer-grade wearable that’s designed to provide
some relief.” CRN included Quell as one of “25 Hot Products at CES”.
Interest from global retailers has been strong as the product brings a
new level of benefit and relevance to the wearable technology category.
Consumers and medical professionals can now visit QuellRelief.com
to learn more and sign up to receive information. The company expects to
begin taking pre-orders for Quell in March and to ship during the second
quarter. Quell will initially be available exclusively through doctor’s
office and online.
“We were pleased with the response to Quell at CES. Clearly there is a
need for wearable technology that makes a meaningful and clear
difference in people’s lives,” said Shai N. Gozani, M.D., Ph.D.,
President and Chief Executive Officer of NeuroMetrix.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. For more information, please visit http://www.NeuroMetrix.com.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150107005791r1&sid=ntxv4&distro=nx&lang=en)
Copyright Business Wire 2015